ArticlePloS one2026
Antimicrobial and antibiofilm evaluation of thymol, sodium azide, and sodium lauryl sulfate against multidrug-resistant pathogens: An integrated experimental and computational study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- In Vitro and In Silico Evaluation of the Anti-Infective Potential of EF24-Analogous Curcuminoids: Antiprotozoal Activity and HIV-1 Ribonuclease H Inhibition.Pathogens (Basel, Switzerland) · 2026Article
- Antibacterial Packaging for Cheese Based on Carboxymethyl Cellulose Composite with Zinc Oxide and Thyme Essential Oil.Foods (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant (MDR) pathogens represent a major global health challenge, underscoring the urgent need for new antimicrobial strategies that can effectively target both planktonic cells and biofilm-associated infections. This study integrated in vitro antimicrobial and antibiofilm assays with comprehensive in silico analyses to evaluate the repurposing potential of thymol (TM), sodium azide (SA), and sodium lauryl sulfate (SLS) against 17 bacterial and two fungal strains, including methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates. TM showed the strongest overall antimicrobial activity, with low MIC/MBC values (0.10-0.20 mg/mL) and potent antibiofilm effects (MBIC: 0.20-0.39 mg/mL; MBEC: 0.39-0.78 mg/mL). In contrast, SA exhibited similar MICs (0.10-0.78 mg/mL) but required much higher concentrations for bactericidal and antibiofilm endpoints (MBC/MBIC/MBEC 6.25-100 mg/mL), whereas SLS displayed variable activity, with low MICs against most Gram-positive bacteria (0.10-0.20 mg/mL) but high MBC/MBIC/MBEC values (50-100 mg/mL), especially for Gram-negative biofilms. Molecular docking and 300 ns molecular dynamics (MD) simulations revealed that TM forms stable complexes with key microbial targets, most notably FtsZ (ΔG = -11.0 kcal/mol; Kd = 3.2 × 10 ⁻ ¹⁰ M), supported by favorable MM/GBSA binding energies and restrained motions in principal component analysis/free-energy landscape (PCA/FEL) analyses. SA and SLS were primarily used as mechanistic comparators (respiratory inhibitors and membrane disruptors, respectively). In contrast, their non-ionic analogs, phenyl azide (PA) and lauryl sulfate (LS), were explored as potential scaffolds. LS showed a very high predicted affinity for UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) (ΔG = -19.9 kcal/mol; Kd = 1.7 × 10 ⁻ ¹¹ M), indicating promise for future optimization. In silico ADMET profiling identified TM as the most balanced candidate, combining broad-spectrum antibiofilm efficacy with a comparatively favorable predicted safety profile. Overall, TM emerges as a viable repurposable antimicrobial agent, whereas LS-based derivatives represent computationally prioritized scaffolds that warrant further experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.